Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates

E Brouillet, P Hantraye, R J Ferrante, R Dolan, A Leroy-Willig, N W Kowall, M F Beal, E Brouillet, P Hantraye, R J Ferrante, R Dolan, A Leroy-Willig, N W Kowall, M F Beal

Abstract

Although the gene defect responsible for Huntington disease (HD) has recently been identified, the pathogenesis of the disease remains obscure. One potential mechanism is that the gene defect may lead to an impairment of energy metabolism followed by slow excitotoxic neuronal injury. In the present study we examined whether chronic administration of 3-nitropropionic acid (3-NP), an irreversible inhibitor of succinate dehydrogenase, can replicate the neuropathologic and clinical features of HD in nonhuman primates. After 3-6 weeks of 3-NP administration, apomorphine treatment induced a significant increase in motor activity as compared with saline-treated controls. Animals showed both choreiform movements, as well as foot and limb dystonia, which are characteristic of HD. More prolonged 3-NP treatment in two additional primates resulted in spontaneous dystonia and dyskinesia accompanied by lesions in the caudate and putamen seen by magnetic resonance imaging. Histologic evaluation showed that there was a depletion of calbindin neurons, astrogliosis, sparing of NADPH-diaphorase neurons, and growth-related proliferative changes in dendrites of spiny neurons similar to changes in HD. The striosomal organization of the striatum and the nucleus accumbens were spared. These findings show that chronic administration of 3-NP to nonhuman primates can replicate many of the characteristic motor and histologic features of HD, further strengthening the possibility that a subtle impairment of energy metabolism may play a role in its pathogenesis.

References

    1. Proc Natl Acad Sci U S A. 1977 Sep;74(9):3767-71
    1. J Neurochem. 1992 Oct;59(4):1211-20
    1. J Neuropathol Exp Neurol. 1985 Nov;44(6):559-77
    1. Nature. 1986 May 8-14;321(6066):168-71
    1. J Neuropathol Exp Neurol. 1987 Jan;46(1):12-27
    1. Acta Neuropathol. 1987;72(3):286-97
    1. Brain Res. 1987 May 12;411(1):162-6
    1. Science. 1988 Aug 19;241(4868):981-3
    1. Brain Res. 1988 Jun 7;451(1-2):205-12
    1. N Engl J Med. 1990 May 3;322(18):1293-8
    1. Brain. 1990 Apr;113 ( Pt 2):509-35
    1. Exp Neurol. 1990 May;108(2):91-104
    1. J Pharmacol Exp Ther. 1990 Jun;253(3):1285-92
    1. J Pharmacol Exp Ther. 1991 May;257(2):870-8
    1. J Neurosci. 1991 Jun;11(6):1649-59
    1. J Neurosci. 1991 Dec;11(12):3877-87
    1. Can J Neurol Sci. 1991 Nov;18(4):492-8
    1. J Neurochem. 1993 Jan;60(1):356-9
    1. Exp Neurol. 1993 Mar;120(1):89-94
    1. Neurology. 1993 Dec;43(12):2689-95
    1. Eur J Pharmacol. 1993 Oct 1;248(3):223-8
    1. J Appl Physiol (1985). 1994 Oct;77(4):1678-84
    1. Neurology. 1992 Apr;42(4):733-8
    1. Proc Natl Acad Sci U S A. 1992 May 1;89(9):4187-91
    1. Ann Neurol. 1992 Feb;31(2):119-30
    1. Exp Neurol. 1992 Oct;118(1):18-23
    1. Neuropathol Appl Neurobiol. 1982 Sep-Oct;8(5):377-93

Source: PubMed

3
Suscribir